Duvelisib (IPI-145, INK1197)
10mM in DMSO
- Product Code: 168779
CAS:
1201438-56-3
| Molecular Weight: | 416.86 g./mol | Molecular Formula: | C₂₂H₁₇ClN₆O |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C |
Product Description:
Duvelisib is used as a targeted therapy in the treatment of certain blood cancers, particularly chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and relapsed or refractory follicular lymphoma. It functions by inhibiting phosphoinositide 3-kinase (PI3K) enzymes, specifically the delta and gamma isoforms, which play key roles in B-cell signaling, survival, and proliferation. By blocking these pathways, duvelisib promotes apoptosis and reduces tumor growth in malignant B-cells.
It is especially considered for patients who have not responded to or have relapsed after other treatments, including chemoimmunotherapy or targeted agents. Due to its mechanism, duvelisib offers a therapeutic option in cases where conventional therapies are no longer effective. Its oral administration also provides a convenient treatment route in outpatient settings. However, clinical use requires careful monitoring for immune-related adverse effects, such as pneumonitis, colitis, and infections, due to its impact on immune cell function.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 1ml | 10-20 days | ฿8,910.00 |
+
-
|
Duvelisib (IPI-145, INK1197)
Duvelisib is used as a targeted therapy in the treatment of certain blood cancers, particularly chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and relapsed or refractory follicular lymphoma. It functions by inhibiting phosphoinositide 3-kinase (PI3K) enzymes, specifically the delta and gamma isoforms, which play key roles in B-cell signaling, survival, and proliferation. By blocking these pathways, duvelisib promotes apoptosis and reduces tumor growth in malignant B-cells.
It is especially considered for patients who have not responded to or have relapsed after other treatments, including chemoimmunotherapy or targeted agents. Due to its mechanism, duvelisib offers a therapeutic option in cases where conventional therapies are no longer effective. Its oral administration also provides a convenient treatment route in outpatient settings. However, clinical use requires careful monitoring for immune-related adverse effects, such as pneumonitis, colitis, and infections, due to its impact on immune cell function.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :